Mirum Pharmaceuticals Acquires San Diego-based Satiogen

Obtains all Satiogen licensing payments and Satiogen-owned intellectual property relating to LIVMARLI and volixibat.

Author Image

By: Charlie Sternberg

Associate Editor

Mirum Pharmaceuticals Inc. has acquired Satiogen Pharmaceuticals Inc., a San Diego-based company.   Satiogen, now a wholly-owned Mirum subsidiary, was an existing licensing partner for LIVMARLI (maralixibat) oral solution and volixibat. Through the transaction, Mirum obtained all Satiogen licensing payments and Satiogen-owned intellectual property relating to LIVMARLI and volixibat.   “The acquisition of Satiogen is a strategic step that consolidates the economics of our commercial and pipel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters